Investment

Features

Pro Tools for Pro Traders

Uncover the powerful trading features

Pro Features

Pluang Web Trading

Leverage

Built for Investors

Experience investing with simplified features

Pockets

Recurring Buy

USD Yield

Pluang Cuan

Fees

Safety

Academy

Latest for You

Get up-to-date financial news and investing tips & information

Blog

Find various tips & information to become a knowledgeable investor

News and Analysis

Read the latest information about finance and investment

Learn

Become a smarter investor by learning the basics of investing

Glossary

Learn investment terms to understand investing better

Promo & Referral

Discover exclusive opportunities to level up your investments

Investment Clubs (Coming Soon)

Join hands with like-minded investors to grow wealth together

Press (Coming Soon)

Stay updated with our latest news and media coverage

Support

About Us

Contact

Ask

Career

Tax Reporting Guide

Pluang+

Adaptive Biotechnologies Corp (ADPT) Stock Price Today

Overview

Financial

Technicals

Analysis

Corporate Action

About

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Technical Indicators

Overall Summary

Bearish (6)

Neutral (9)

Bullish (12)

Performance

ADPT ROI

-13.4%

% from 52W High

-15.25%

$4.78

52W Low: $2.34

18 Apr 2024

52W High: $5.64

27 Sep 2023

News

Zacks Investment

2mo

Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up - Zacks Investment Research

Benzinga

3mo

Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor

Globe Newswire

4mo

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Globe Newswire

4mo

Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

The Motley Fool

4mo

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions